BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.

Mutations in breast cancer-associated 1 (BRCA1) increase the lifetime risk of developing breast cancer by up to 51% over the risk of the general population. Many aspects of this multifunctional protein have been revealed, including its essential role in homologous recombination repair, E3 ubiquitin ligase activity, transcriptional regulation, and apoptosis. Although most studies have focused on BRCA1 deficiency due to mutations, only a minority of patients carry BRCA1 mutations. A recent study has suggested an expanded definition of BRCA1 deficiency with reduced BRCA1 levels, which accounts for almost half of all triple-negative breast cancer (TNBC) patients. Reduced BRCA1 levels can result from epigenetic modifications or increased proteasomal degradation. In this review, we discuss how this knowledge of BRCA1 function and regulation of BRCA1 protein stability can help overcome the challenges encountered in the clinic and advance current treatment strategies for BRCA1-related breast cancer patients, especially focusing on TNBC.

• Publication year

  2022

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  2022-12-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2022.114090PMID 36493696
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The BRCA1/BARD1 ubiquitin ligase and its substrates.

  2021cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation

  2021cited by this paper
• BRCA1 degradation in response to mitochondrial damage in breast cancer cells

  2021cited by this paper
• Highly accurate protein structure prediction with AlphaFold

  2021cited by this paper
• AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models

  2021cited by this paper
• Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers

  2020cited by this paper
• NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation

  2020cited by this paper
• PRMT1-dependent methylation of BRCA1 contributes to the epigenetic defense of breast cancer cells against ionizing radiation

  2020cited by this paper
• The BRCA Tumor Suppressor Network in Chromosome Damage Repair by Homologous Recombination.

  2019cited by this paper
• Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).

  2018cited by this paper
• Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

  2018cited by this paper
• Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells

  2018cited by this paper
• Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation

  2018cited by this paper
• GUARDIN is a p53-responsive long non-coding RNA that is essential for genomic stability

  2018cited by this paper
• BRCA1 function in the intra-S checkpoint is activated by acetylation via a pCAF/SIRT1 axis

  2018cited by this paper
• BRCA1–BARD1 promotes RAD51-mediated homologous DNA pairing

  2017cited by this paper
• BRCA1 and BRCA2 mutations and treatment strategies for breast cancer.

  2017cited by this paper
• Comprehensive analysis of BRCA1 and BRCA2 germline mutations in a large cohort of 5931 Chinese women with breast cancer

  2016cited by this paper
• Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.

  2016cited by this paper
• NPR3 protects cardiomyocytes from apoptosis through inhibition of cytosolic BRCA1 and TNF-α

  2016cited by this paper
• The BRCA1 Tumor Suppressor Binds to Inositol 1,4,5-Trisphosphate Receptors to Stimulate Apoptotic Calcium Release*

  2015cited by this paper
• Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis

  2015cited by this paper
• TUSC4 functions as a tumor suppressor by regulating BRCA1 stability.

  2015cited by this paper
• BRCA1 regulates PIG3-mediated apoptosis in a p53-dependent manner

  2015cited by this paper
• Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

  2015cited by this paper
• 53BP1, BRCA1, and the Choice between Recombination and End Joining at DNA Double-Strand Breaks

  2014cited by this paper
• HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.

  2014cited by this paper
• DNA repair: Making the cut

  2014cited by this paper
• Effect of BRCA1 immunohistochemical localizations on prognosis of patients with sporadic breast carcinomas.

  2014cited by this paper
• Opportunities and hurdles in the treatment of BRCA1-related breast cancer

  2014cited by this paper
• DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability

  2014cited by this paper
• Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

  2014cited by this paper
• A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice.

  2013cited by this paper
• Chromatin remodeling, BRCA1, SAHF and cellular senescence

  2013cited by this paper
• Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation.

  2013cited by this paper
• HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response

  2013cited by this paper
• Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations

  2012cited by this paper
• Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.

  2012cited by this paper
• The F-box Protein FBXO44 Mediates BRCA1 Ubiquitination and Degradation*

  2012cited by this paper
• Structure-Function of the Tumor Suppressor BRCA1

  2012cited by this paper
• GADD45 proteins: central players in tumorigenesis.

  2012cited by this paper
• Characterization of BRCA1 Protein Targeting, Dynamics, and Function at the Centrosome

  2012cited by this paper
• The BRCA1 Breast Cancer Suppressor: Regulation of Transport, Dynamics, and Function at Multiple Subcellular Locations

  2012cited by this paper
• BRCA1 and GATA3 corepress FOXC1 to inhibit the pathogenesis of basal-like breast cancers

  2012cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

  2011cited by this paper
• Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.

  2011cited by this paper
• Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.

  2011cited by this paper
• p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage.

  2011cited by this paper
• BRCT domains

  2011cited by this paper
• Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations

  2011cited by this paper
• Bcl-2 inhibits nuclear homologous recombination by localizing BRCA1 to the endomembranes.

  2011cited by this paper
• On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations

  2011cited by this paper
• Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications.

  2011cited by this paper
• Sporadic breast carcinomas with somatic BRCA1 gene deletions share genotype/phenotype features with familial breast carcinomas.

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• The role of BRCA1 in DNA damage response

  2010cited by this paper
• BRCA1 and its toolbox for the maintenance of genome integrity

  2010cited by this paper
• DNA damage-induced cytotoxicity is dissociated from BRCA1's DNA repair function but is dependent on its cytosolic accumulation.

  2010cited by this paper
• The BRCA‐1 binding protein BRAP2 is a novel, negative regulator of nuclear import of viral proteins, dependent on phosphorylation flanking the nuclear localization signal

  2010cited by this paper
• Differential modulation of BRCA1 and BARD1 nuclear localisation and foci assembly by DNA damage.

  2010cited by this paper
• BACH1/FANCJ acts with TopBP1 and participates early in DNA replication checkpoint control.

  2010cited by this paper
• HERC2 is an E3 ligase that targets BRCA1 for degradation.

  2010cited by this paper
• BRCA1 16 years later: DNA damage‐induced BRCA1 shuttling

  2010cited by this paper
• Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.

  2010cited by this paper
• Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.

  2010cited by this paper
• BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast‐ovarian cancer

  2009cited by this paper
• Genomic actions of estrogen receptor alpha: what are the targets and how are they regulated?

  2009cited by this paper
• The Contribution of BRCA1 and BRCA2 to Ovarian Cancer

  2009cited by this paper
• Triple negative breast cancers: clinical and prognostic implications.

  2009cited by this paper
• 14-3-3 proteins, FHA domains and BRCT domains in the DNA damage response.

  2009cited by this paper
• Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells.

  2008cited by this paper
• Mechanism of eukaryotic homologous recombination.

  2008cited by this paper
• The ubiquitin E3 ligase activity of BRCA1 and its biological functions

  2008cited by this paper
• Membrane association of estrogen receptor alpha and beta influences 17beta-estradiol-mediated cancer cell proliferation.

  2008cited by this paper
• A mechanism for transcriptional repression dependent on the BRCA1 E3 ubiquitin ligase

  2007cited by this paper
• Ubiquitination and proteasome-mediated degradation of BRCA1 and BARD1 during steroidogenesis in human ovarian granulosa cells.

  2007cited by this paper
• CCDC98 is a BRCA1-BRCT domain–binding protein involved in the DNA damage response

  2007cited by this paper
• Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response

  2007cited by this paper
• Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response

  2007cited by this paper
• BRCA1 dysfunction in sporadic basal-like breast cancer

  2007cited by this paper
• Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations

  2007cited by this paper
• Is there more to BARD1 than BRCA1?

  2006cited by this paper
• The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly.

  2006cited by this paper
• Identification of domains of BRCA1 critical for the ubiquitin-dependent inhibition of centrosome function.

  2006cited by this paper
• An Amino-terminal Motif Functions as a Second Nuclear Export Sequence in BRCA1*

  2005cited by this paper
• Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking

  2005cited by this paper
• ATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex

  2005cited by this paper
• SQ/TQ cluster domains: concentrated ATM/ATR kinase phosphorylation site regions in DNA‐damage‐response proteins

  2005cited by this paper
• Survival versus apoptotic 17β‐estradiol effect: Role of ERα and ERβ activated non‐genomic signaling

  2005cited by this paper
• DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains

  2004cited by this paper
• Nucleophosmin/B23 Is a Candidate Substrate for the BRCA1-BARD1 Ubiquitin Ligase*

  2004cited by this paper
• Nuclear–cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1

  2004cited by this paper
• Direct Activation of the ATM Protein Kinase by the Mre11/Rad50/Nbs1 Complex

  2004cited by this paper
• Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria.

  2004cited by this paper
• Survival and Recurrence After Breast Cancer in BRCA1/2 Mutation Carriers

  2004cited by this paper
• BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention.

  2004cited by this paper
• Ubiquitin and breast cancer

  2004cited by this paper
• Ubiquitination and Proteasomal Degradation of the BRCA1 Tumor Suppressor Is Regulated during Cell Cycle Progression*

  2004cited by this paper
• Mass Spectrometric and Mutational Analyses Reveal Lys-6-linked Polyubiquitin Chains Catalyzed by BRCA1-BARD1 Ubiquitin Ligase*

  2004cited by this paper

• Discovery of novel olaparib-β-carboline hybrids for treating BRCA-deficient triple negative breast cancer.

  2026cites this paper
• Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies

  2025cites this paper
• Establishing the First Genetic Variant Registry for Breast and Ovarian Cancer in Colombia: Insights and Implications

  2025cites this paper
• Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer.

  2025cites this paper
• Resolving tumor microenvironment heterogeneity to forecast immunotherapy response in triple-negative breast cancer through multi-scale analysis

  2025cites this paper
• Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for BRCA1-Associated Triple-Negative Breast Cancer

  2025cites this paper
• IL-6 Blockade Enhances the Efficacy of CDK4/6 Inhibitor in BRCA1-Mutant Triple-Negative Breast Cancer Cells

  2025cites this paper
• The breakome of BRCA1 and BRCA2 pathway mutation carriers reveals early processes in breast oncogenesis

  2025cites this paper
• Dissecting the Non-Immune Tumor Microenvironment in Triple-Negative Breast Cancer: Molecular Subtype-Specific Patterns and Prognostic Implications

  2025cites this paper
• VITAMIN D–VITAMIN D RECEPTOR AXIS IN BREAST CANCER: MECHANISMS, EVIDENCE, AND CLINICAL IMPLICATIONS

  2025cites this paper
• Molecular Docking: An Emerging Tool for Target-Based Cancer Therapy.

  2025cites this paper
• A non-inferiority, phase III trial of gemcitabine plus capecitabine versus gemcitabine plus carboplatin as first-line therapy and tumor-infiltrating lymphocytes as a prognostic biomarker in patients with advanced triple-negative breast cancer

  2024cites this paper
• maGENEgerZ: An Efficient AI-Based Framework Can Extract More Expressed Genes and Biological Insights Underlying Breast Cancer Drug Response Mechanism

  2024cites this paper
• Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple‐negative breast cancer cells

  2024cites this paper
• Chemoresistance to additive PARP/PI3K dual inhibition in triple-negative breast cancer cell lines is associated with adaptive stem cell-like prevalence

  2024cites this paper
• maGENEgerZ: An Efficient Artificial Intelligence-Based Framework Can Extract More Expressed Genes and Biological Insights Underlying Breast Cancer Drug Response Mechanism

  2024cites this paper
• Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer.

  2024cites this paper
• Aqueous Extracts of Ocimum gratissimum Sensitize Hepatocellular Carcinoma Cells to Cisplatin through BRCA1 Inhibition

  2024cites this paper
• Advancements in Early Detection and Screening Strategies for Pancreatic Cancer: From Genetic Susceptibility to Novel Biomarkers

  2024cites this paper
• Phosphorylation of BRCA1 at serine 1387 plays a critical role in cathepsin S-mediated radiation resistance via BRCA1 degradation and BCL2 stabilization.

  2024cites this paper
• Triple-Action Therapy: Combining Machine Learning, Docking, and Dynamics to Combat BRCA1-Mutated Breast Cancer

  2024cites this paper
• Updates on Triple-Negative Breast Cancer in Type 2 Diabetes Mellitus Patients: From Risk Factors to Diagnosis, Biomarkers and Therapy

  2023cites this paper